Genetics of human coronary vasomotion

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 3, 2004, Pages 255-260

  Naber, C K ^a   Siffert, W ^a   Erbel, R ^a   Heusch, G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Coronary vasomotion; Genetic polymorphisms; Pathophysiologic relevance

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA3 SUBUNIT; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ALPHA 2 ADRENERGIC RECEPTOR GENE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CORONARY ARTERY; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; GUANINE NUCLEOTIDE BINDING PROTEIN BETA3 SUBUNIT GENE; HUMAN; NONHUMAN; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOMOTOR REFLEX;

ADULT; AGED; ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; CORONARY VESSELS; GENETIC PREDISPOSITION TO DISEASE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTION; VASOMOTOR SYSTEM;

EID: 1842429939     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Heusch G, Erbel R, Siffert W. Genetic determinants of coronary vasomotor tone in humans. Am J Physiol Heart Circ Physiol 2001; 281: H1465-H1468.
2. Soubrier F, Jeunemaitre X, Rigat B, Houot AM, Cambien F, Corvol P. Similar frequencies of renin gene restriction fragment length polymorphisms in hypertensive and normotensive subjects. Hypertension 1990; 16: 712-7.
3. Heusch G. Control of coronary vasomatar tone in ischaemic myocardium by local metabolism and neurohumoral mechanisms. Eur Heart J 1991; 12 (Suppl. F): 99-106.
4. Heusch G, Baumgart D, Camici P et al. Alpha-adreneraic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000; 101: 689-94.
5. Heusch G. Emerging importance of alpha-adrenergic coronary vasoconstriction in acute coronary syndromes and its genetic background. J Am Coll Cardiol 2003; 41: 195-6.
6. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115-22.
7. Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
8. Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol 1999; 33: 796-804.
9. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003; 362: 782-8.
10. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
11. Keavney B, McKenzie C, Parish S et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5 000 cases and 6 000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355: 434-42.
12. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20: 484-92.
13. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708-12.
14. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
15. Arcaro G, Solini A, Monauni T et al. ACE genotype and endothelium-dependent vasodilation of conduit arteries and forearm microcirculation in humans. Arterioscler Thromb Vasc Biol 2001; 21: 1313-9.
16. Butler R, Morris AD, Burchell B, Struthers AD. DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 1999; 33: 1164-8.
17. Perticone F, Ceravolo R, Maio R et al. Angiotensin-converting enzyme gene polymorphism is associated with endothelium-dependent vasodilation in never treated hypertensive patients. Hypertension 1998; 31: 900-5.
18. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996; 17: 787-94.
19. Rossi GP, Taddei S, Virdis A et al. Exclusion of the ACE D/I gene polymorphism as a determinant of endothelial dysfunction. Hypertension 2001; 37: 293-300.
20. Celermajer DS, Sorensen KE, Barley J, Jeffrey S, Carter N, Deanfield J. Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. Atherosclerosis 1994; 11: 121-6.
21. Gainer IV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity. Hypertension 2001; 37: 46-51.
22. Kurland L, Melhus H, Sarabi M, Millgard J, Ljunghall S, Lind L. Polymorphisms in the renin-angiotensin system and endothelium-dependent vasodilation in normotensive subjects. Clin Physiol 2001; 21: 343-9.
23. Kario K, Matsuo T, Kobayashi H et al. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol 1998; 32: 444-50.
24. Makris TK, Stavroulakis GA, Dafni UG et al. ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension. Am Heart J 2000; 140: 760-5.
25. Prasad A, Narayanan S, Waclawiw MA, Estein N, Quyyumi AA. The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000; 36: 1579-86.
26. Mulder HJ, van Geel PP, Schalij MJ, van Gilst WH, Zwinderman AH, Bruschke AV. DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart 2003; 89: 557-8.
27. Prasad A, Husain S, Schenke W, Mincemoyer R, Epstein N, Quyyumi AA. Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans. J Am Coll Cardiol 2000; 36: 1467-73.
28. Prasad A, Narayanan S, Husain S et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000; 102: 35-41.
29. Van Gel PP, Pinto YM, Voors AA et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000; 35: 717-21.
30. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990; 66: 1561-75.
31. Nakayama M, Yasue H, Yoshimura M et al. T-786→C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-70.
32. Tanus-Santos JE, Desai M, Deak LR et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002; 12: 407-13.
33. Colombo MG, Paradossi U, Andreassi MG et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003; 49: 389-95.
34. Gomma AH, Elrayess MA, Knight CJ, Hawe E, Fox KM, Humphries SE. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 2002; 23: 1955-62.
35. Yoshimura M, Nakayama M, Shimasaki Y et al. A T-786→C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene and coronary arterial vasomotility. Am J Cardiol 2000; 85: 710-4.
36. Rossi GP, Taddei S, Virdis A et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41: 938-45.
37. CK Naber, O Oldenburg, U Frey et al. Relevance of the T-786C and Glu298Asp variants in the endothelial nitric oxide synthase gene for cholinergic and adrenergic coronary vasomotor responses in man. Circulation 2003; 106 (Suppl): 1042 (Abstract).
38. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)→Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 26674-9.
39. Tesauro M, Thampson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary at diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 2000; 97: 2832-5.
40. Hingorani AD, Liang CF, Fatibene J et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-20.
41. Miyamoto Y, Saito Y, Kajiyama N et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32: 3-8.
42. Shimasaki Y, Yasue H, Yoshimura M et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998; 31: 1506-10.
43. Naber CK, Baumgart D, Altmann C, Siffert W, Erbel R, Heusch G. eNOS 894T allele and coronary blood flow at rest and during adenosine-induced hyperemia. Am J Physiol Heart Circ Physiol 2001; 281: H1908-H1912.
44. Guzik TJ, Black E, West NE et al. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 2001; 100: 130-7.
45. Leeson CP, Hingorani AD, Mullen MJ et al. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90: 1153-8.
46. Schneider MP, Erdmann J, Delles C, Fleck E, Regitz-Zagrosek V, Schmieder RE. Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens 2000; 18: 1767-73.
47. Rossi GP, Cesari M, Zanchetta M et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 2003; 41: 930-7.
48. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11: 719-25.
49. Tsujita Y, Baba S, Yamauchi R et al. Association analyses between genetic polymorphisms of endothelial nitric oxide synthase gene and hypertension in Japanese: The Suita Study. J Hypertens 2001; 19: 1941-8.
50. Baumgart D, Haude M, Gorge G et al. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999; 99: 2090-7.
51. Snapir A, Mikkelsson J, Perola M, Penttila A, Scheinin M, Karhunen PJ. Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 2003; 41: 190-4.
52. Snapir A, Heinonen P, Tuomainen TP et al. An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001; 37: 1516-22.
53. Snapir A, Koskenvuo J, Taikka J et al. Effects of common polymorphisms in the alpha 1A-, alpha2B-, beta1- and beta2-adrenoreceptors on haemodynamic responses to adrenaline. Clin Sci (Lond) 2003; 104: 509-20.
54. Heinonen P, Jartti L, Jarvisalo MJ et al. Deletion polymorphism in the alpha2B-adrenergic receptor gene is associated with flow-mediated dilatation of the brachial artery. Clin Sci (Lond) 2002; 103: 517-24.
55. Baumgart D, Naber C, Haude M et al. G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on algha(2)-adrenoceptor activation. Circ Res 1997; 85: 965-9.
56. Siffert W, Rosskopf D, Siffert G et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 45-8.
57. Naber C, Hermann BL, Vietzke D et al. Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Lett 2000; 484: 199-201.
58. Liao X, Homey O. The release of endothelium-derived relaxing factor via alpha 2-adrenergic-receptor activation is specifically mediated by Gi alpha 2. J Biol Chem 1993; 268: 19528-33.
59. Naber CK, Baumgart D, Heusch G et al. Role of the eNOS Glu298Asp variant an the GNB3825T allele dependent determination of alpha-adrenergic caronary constriction. Pharmacogenetics 2003; 13: 279-84.